Altered expression and coregulation of dopamine signalling genes in schizophrenia and bipolar disorder

Neuropathology and Applied Neurobiology

Volumn 37, Issue 2, 2011, Pages 206-219

  Zhan, L ^a   Kerr, J R ^a   Lafuente, M J ^e   Maclean, A ^c   Chibalina, M V ^d   Liu, B ^f   Burke, B ^a   Bevan, S ^b   Nasir, J ^a  

^a Clinical Developmental Sciences ^*  (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e GLAXOSMITHKLINE   (Spain)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

Dopamine; Dopamine receptor interacting protein; Dopamine signalling; Schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE INTERACTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

BIPOLAR DISORDER; CLUSTER ANALYSIS; DOPAMINE; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; FEMALE; GENE EXPRESSION; GTP-BINDING PROTEINS; HUMANS; MALE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, DOPAMINE; RECEPTORS, DOPAMINE D2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 78651085055     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2010.01128.x     Document Type: Article

References (60)

1. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992; 13: 61-9
2. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998; 78: 189-225
3. Greengard P. The neurobiology of slow synaptic transmission. Science 2001; 294: 1024-30
4. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P. Diverse psychotomimetics act through a common signalling pathway. Science 2003; 302: 1412-15
5. Carlsson A. A paradigm shift in brain research. Science 2001; 294: 1021-4
6. Tenn CC, Fletcher PJ, Kapur S. Amphetamine-sensitized animals show a sensorimotor gating and behavioural abnormality similar to that of schizophrenia. Schizophr Res 2003; 64: 103-14
7. Peleg-Raibstein D, Knuesel I, Feldon J. Amphetamine sensitization in rats as an animal model of schizophrenia. Behav Brain Res 2008; 191: 190-201
8. Bonci A, Hopf FW. The dopamine D2 receptor: new surprises from an old friend. Neuron 2005; 47: 335-8
9. Ross CA, Margolis RL, Reading SAJ, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006; 52: 139-53
10. Stroup TS, Alves WM, Hamer RM, Lieberman JA. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 2006; 5: 133-46
11. Fields S, Song O. A novel genetic system to detect protein-protein interaction. Nature 1989; 340: 245-6
12. 2+ connection in dopamine signalling. Trends Pharmacol Sci 2003; 24: 486-92
13. Bermak JS, Li M, Bullock C, Zhou Q-Y. Regulation of transport of the dopamine D1 receptor by a new membrane-associated ER protein. Nat Cell Biol 2001; 3: 492-8
14. 1 dopamine receptor to regulate cell surface expression and desensitization. J Neurosci 2002; 22: 5920-30
15. Smith FD, Oxford GS, Milgram SL. Association of the D2 dopamine receptor third cytoplasmic loop with Spinophilin, a protein phosphotase-1-interacting protein. J Biol Chem 1991; 274: 19894-900
16. Binda AV, Kabbani N, Lin R, Levenson R. D2 and D3 dopamine receptor cell surface localization mediated by interaction with protein 4.1N. Mol Pharmacol 2002; 62: 507-13
17. Park SK, Nguyen MD, Fischer A, Luke MP, Affar el B, Dieffenbach PB, Tseng HC, Shi Y, Tsai LH. Par-4 links dopamine signalling and depression. Cell 2005; 122: 275-87
18. Zhan L, Liu B, Jose-Lafuente M, Chibalina MV, Grierson A, Maclean A, Nasir J. ALG-2 interacting protein AIP1: a novel link between D1 and D3 signalling. Eur J Neurosci 2008; 27: 1626-33
19. Hu Z, Snitkin ES, DeLisi C. VisANT: an integrative framework for networks in systems biology. Brief Bioinform 2008; 9: 317-25
20. Kerr JR, Petty R, Burke B, Gough J, Fear D, Sinclair LI, Mattey DL, Richards SC, Montgomery J, Baldwin DA, Kellam P, Harrison TJ, Griffin GE, Main J, Enlander D, Nutt DJ, Holgate ST. Gene expression subtypes in patients with chronic fatigue syndrome/myalgic encephalomyelitis. J Infect Dis 2008; 197: 1171-84
21. Liu DW, Chen ST, Liu PH. Choice of endogenous control for gene expression in nonsmall cell lung cancer. Eur Respir J 2005; 26: 1002-8
22. Medhurst AD, Harrison DC, Read SJ, Campbell CA, Robbins MJ, Pangalos MN. The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and animal models. J Neurosci Methods 2000; 98: 9-20
23. Gutala RV, Reddy PH. The use of real-time PCR analysis in a gene expression study of Alzheimer's disease post-mortem brains. J Neurosci Methods 2004; 132: 101-7
24. Ding L, Hegde AN. Expression of RGS4 splice variants in dorsolateral prefrontal cortex of schizophrenia and bipolar disorder patients. Biol Psychiatry 2009; 65: 541-5
25. Bai J, He F, Novikova SI, Undie AS, Dracheva S, Haroutunian V, Lidow MS. Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biol Psychiatry 2004; 56: 427-40
26. Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 2004; 9: 299-307
27. Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, Faull RLM, Mckenna PJ, Jones PB, Arai H, Starkey M, Emson PC, Bahn S. Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci U S A 2002; 99: 4680-5
28. Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry 1997; 54: 1089-95
29. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002; 18: 207-8
30. Talkowski ME, Kirov G, Bamne M, Georgieva L, Torres G, Mansour H, Chowdari KV, Milanova V, Wood J, McClain L, Prasad K, Shirts B, Zhang J, O'Donovan MC, Owen MJ, Devlin B, Nimgaonkar VL. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum Mol Genet 2008; 17: 747-58
31. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 2008; 40: 827-34
32. Bi W, Sapir T, Shchelochkov OA, Zhang F, Withers MA, Hunter JV, Levy T, Shinder V, Peiffer DA, Gunderson KL, Nezarati MM, Shotts VA, Amato SS, Savage SK, Harris DJ, Day-Salvatore DL, Horner M, Lu XY, Sahoo T, Yanagawa Y, Beaudet AL, Cheung SW, Martinez S, Lupski JR, Reiner O. Increased LIS1 expression affects human and mouse brain development. Nat Genet 2009; 41: 168-77
33. Xu B, Wratten N, Charych EI, Buyske S, Firestein BL, Brzustowicz LM. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Med 2005; 2: 999-1007
34. Anitha A, Nakamura K, Yamada K, Iwayama Y, Toyota T, Takei N, Iwata Y, Suzuki K, Sekine Y, Matsuzaki H, Kawai M, Miyoshi K, Katayama T, Matsuzaki S, Baba K, Honda A, Hattori T, Shimizu S, Kumamoto N, Tohyama M, Yoshikawa T, Mori N. Gene and expression analyses reveal enhanced expression of pericentrin 2 (PCNT2) in bipolar disorder. Biol Psychiatry 2008; 63: 678-85
35. Koh PO, Undie AS, Kabbani N, Levenson R, Goldman-Rakic PS, Lidow MS. Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenia and bipolar patients. Proc Natl Acad Sci U S A 2003; 100: 313-17
36. 1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology 2009; 206: 313-24
37. 108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001; 98: 6917-22
38. Feldcamp LA, Souza RP, Romano-Silva M, Kennedy JL, Wong AHC. Reduced prefrontal cortex DARPP-32 mRNA in complete suicide victims with schizophrenia. Schizophr Res 2008; 103: 192-200
39. Baracskay KL, Haroutunian V, Meador-Woodruff JH. Dopamine receptor signalling molecules are altered in elderly schizophrenic cortex. Synapse 2006; 60: 271-9
40. Albert KA, Hemmings HC Jr, Adamo AIB, Potkin SG, Akbarian S, Sandman CA, Cotman CW, Bunney WE Jr, Greengard P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 2002; 59: 705-12
41. Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-base study. Lancet 2009; 373: 234-9
42. Moskvina V, Craddock C, Holamans P, Nikolov I, Pahwa JS, Green E, Wellcome Trust Case Control Consortium, Owen MJ, O'Donovan MC. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Mol Psychiatry 2009; 14: 252-60.
43. Iida, S, Seto M, Yamamoto K, Komatsu H, Tojo A, Asano S, Kamada N, Ariyoshi Y, Takahashi T, Ueda R. MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. Oncogene 1993; 8: 3085-92
44. Collins EC, Appert A, Ariza-McNaughton L, Pannell R, Yamada Y, Rabbitts TH. Mouse Af9 is a controller of embryo patterning, like Mll, whose human homologue fuses with AF9 after chromosomal translocation in leukemia. Mol Cell Biol 2002; 22: 7313-24
45. Pramparo T, Grosso S, Messa J, Zatterale A, Bonaglia MC, Chessa L, Balestri P, Rocchi M, Zuffardi O, Giorda R. Loss-of-function mutation of the AF9/MLLT3 gene in a girl with neuromotor development delay, cerebellar ataxia, and epilepsy. Hum Genet 2005; 118: 76-81
46. Guillemot F, Billault A, Auffray C. Physical linkage of a guanine nucleotide-binding protein-related gene to the chicken major histocompatibility complex. Proc Natl Acad Sci U S A 1989; 86: 4594-8
47. Neves SR, Prahlad TR, Iyengar R. G protein pathways. Science 2002; 296: 1636-9
48. Hadano S, Hand CK, Osuga H, Yanagisawa Y, Otomo A, Devon RS, Miyamoto N, Showguchi-Miyata J, Okada Y, Singaraja R, Figlewicz DA, Kwiatkowski T, Hosler BA, Sagie T, Skaug J, Nasir J, Brown RH Jr, Scherer SW, Rouleau GA, Hayden MR, Ikeda JE. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001; 29: 166-73
49. Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL, Zappia M, Nelis E, Patitucci A, Senderek J, Parman Y, Evgrafov O, Jonghe PD, Takahashi Y, Tsuji S, Pericak-Vance MA, Quattrone A, Battaloglu E, Polyakov AV, Timmerman V, Schröder JM, Vance JM. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36: 449-51
50. Verhoeven K, De Jonghe P, Van de Putte T, Nelis E, Zwijsen A, Verpoorten N, De Vriendt E, Jacobs A, Van Gerwen V, Francis A, Ceuterick C, Huylebroeck D, Timmerman V. Slowed conduction and thin myelination of peripheral nerves associated with mutant rho guanine-nucleotide exchange factor 10. Am J Hum Genet 2003; 73: 926-32
51. Williams NM, Glaser B, Norton N, Williams H, Pierce T, Moskvina V, Monks S, Del Favero J, Goossens D, Rujescu D, Giegling I, Kirov G, Craddock N, Murphy KC, O'Donovan MC, Owen MJ. Strong evidence that GNB1L is associated with schizophrenia. Hum Mol Genet 2008; 17: 555-66
52. Lipska BK, Mitkus S, Caruso M, Hyde TM, Chen J, Vakkalanka R, Straub RE, Weinberger DR, Kleinman JE. RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity. Hum Mol Genet 2006; 15: 2804-12
53. Hall H, Sedvall G, Magnusson O, Kopp J, Halldin C, Farde L. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 1994; 11: 245-56
54. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, Terasaki O, Someya Y, Sassa T, Sudo Y, Matsushima E, Iyo M, Tateno Y, Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997; 385: 634-6
55. Snyder S. Dopamine receptor excess and mouse madness. Neuron 2006; 49: 484-5
56. 2 receptors. Psychopharmacology 1993; 112: S40-S54
57. Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O'Dowd BF, George SR. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A 2007; 104: 654-9
58. 4, receptors in the striatum without the involvement of action potentials. J Neurosci 2000; 20: 6666-71
59. 3 Dopamine Receptor heterodimers exhibit unique functional properties. J Biol Chem 2001; 276: 30308-14
60. 1 dopamine receptor in immortalized renal proximal tubule cells. Hypertension 2006; 47: 573-9